Boehringer Mannheim Gmbh

Hoffmann-la Roche Inc.

Roche Diagnostics Operations, Inc.

Roche Diagnostics Gmbh

Boehringer Mannehim Gmbh

F. Hoffmann-la Roche Ag

Alfred Mertens

Wolfgang Von Der Saal

Bernd Muller-Beckmann

Klaus Strein

Harald Zilch

Erwin Boehm

Jens-Peter Holck

Gisbert Sponer

Walter-Gunar Friebe

Wolfgang Kampe

Herbert Berger

Herbert Leinert

Lothar Kling

Dieter Herrmann

Wolfgang Schaumann

Bernhard Konig

Christian Klein

Li Chen

Dieter Heindl

Guy Georges

Christos Tsaklakidis

Michael Schraeml

Gerd Zimmermann

Michael Gerg

Frank Seela

Egon Roesch

Hans Seidel

Michael Tacke

Ulrich Martin

Xihan Wu

Rainer Gumbiowski

Hans-Peter Wolff

Volker Schmid

Helmut Rosemeyer

Hans-Georg Opitz

Monika Soukupova

Peter Freund

Ulrike Leser

Liesel Dorge

Edith Koch

Wolfgang Schafer

Jens-Peter Hoelck

Angelika Roling

Werner Bourgeouis

Claudio Sustmann

Christoph Rutz

Jan Van Dieck

A bivalent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bivalent binding agent, and for use of the disclosed bivalent binding agent in histological staining procedures.

Detection of a posttranslationally modified polypeptide by a bivalent binding agent

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Isoquinoline aminopyrazole derivatives

The present invention is directed to new nucleoside monophosphate derivatives of lipid ester residues of general formula (I) ##STR1## wherein R.sup.1 represents an optionally substituted alkyl chain having 1-20 carbon atoms;

Lipid esters of nucleoside monophosphates and their use as

Pyridine and pyridazine derivatives, processes for the production

Compounds of the formula I ##STR1## in which R.sub.1 and R.sub.2 represent a possibly substituted C.sub.8 -C.sub.15 -alkyl chain, n the number 0, 1 or 2 and A the residue of a nucleoside, processes for their preparation, as well as antiviral medicaments which contain these compounds.

Phospholipid derivatives of nucleosides and their use as anti-viral

Thiazolidinediones and drugs containing them

Liponucleotides containing an ether linkage in the 2-position and a thioether, sulfoxide, or sulfone linkage in the 3-position. The nucleoside component of said liponucleotide is AZT or 3'-deoxy-3'-fluorothymidine. These compounds exhibit antiviral activity.

Phospholipid derivatives of nucleosides

Tricyclic thiazole and oxazole derivatives and pharmaceutical agents

Purine analog nucleoside and nucleotide compounds

Use of thiazoloisoindolinone derivatives as antiviral medicaments

The present invention provides compounds and pharmaceutical compositions containing indolones of the general formula: ##STR1## These indolones where n.dbd.o and the pharmaceutical compositions containing these compounds are used for the treatment of diseases in which erythrocyte and thrombocyte aggregation play an important part, especially for the inhibition of aggregation of these cells.

Pharmaceutical lactam compositions for inhibition of erythrocyte and

Pharmaceutical compositions for inhibiting the aggregation of erthyrocytes or thrombocytes which include phenylamides which conform to the formula: ##STR1## with R.sub.1-6, X, A and B being as defined. Processes for the preparation of novel phenylamides coming within the above formula are also discussed.

Pharmaceutical compositions containing phenylamides

The present invention provides tricyclic benzimidazoles of the formula ##STR1## wherein R.sub.1 is a phenyl radical of the general formula: ##STR2## wherein R.sub.2, R.sub.3 and R.sub.4 can be the same or different as in claim 1. For A, B, C and D are understood those compounds where one or two of A, B, C or D are nitrogen. These compounds are useful to inhibit the aggregation of thrombocytes and erythrocytes, lower blood pressure and can increase the power of the heart.

Tricyclic benzimidazole compounds, pharmaceutical compositions and

The present invention provides compounds of the general formula (I) which inhibit the aggregation of erythrocytes or thrombocytes ##STR1## wherein A is hydrogen or C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -alkynyl, benzyl or C.sub.3 -C.sub.7 -cycloalkyl radical, B is hydrogen, R.sub.1 is a C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl or C.sub.3 -C.sub.7 -cycloalkyl radical, R.sub.2 is a C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.3 -C.sub.7 -cycloalkyl, C.sub.1 -C.sub.6 -alkylcarbonyl, C.sub.1 -C.sub.6 -alkoxycarbonyl, aminocarbonyl or hydrazinocarbonyl radical, or R.sub.1 and R.sub.2, together with the carbon atom to which they are attached, form a C.sub.3 -C.sub.7 -cycloalkyl ring, n is 0, X is a valency bond or a C.sub.1 -C.sub.6 -alkylene radical, R.sub.3 is a carbocyclic aromatic ring, which may be substituted; and the tautomers, optically-active forms and physiologically acceptable salts thereof with organic and inorganic acids.

Bicyclic carboxamides, compositions containing same and use thereof

Lactam compounds of the formula ##STR1## in which: R is hydrogen, alkyl or cycloalkyl;

Ureidoindoles, pharmaceutical compositions and methods for erythrocyte

Growing community of inventors

Schriesheim, Germany

Alfred Mertens